Related references
Note: Only part of the references are listed.Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma
Pamela B. Allen et al.
BLOOD (2021)
Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study
X. Bai et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
Maria V. Deligiorgi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Diabetes Insipidus An Update
Julie Refardt et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2020)
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette et al.
HORMONE AND METABOLIC RESEARCH (2019)
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Radhakrishnan Ramchandren et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
Yuankai Shi et al.
LANCET HAEMATOLOGY (2019)
Anti-PD-L1 Treatment Induced Central Diabetes Insipidus
Chen Zhao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
MECHANISMS IN ENDOCRINOLOGY Hypophysitis: diagnosis and treatment
Mamta N. Joshi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series
Patrizio Caturegli et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
FUTURE ONCOLOGY (2016)
Immune checkpoint inhibitors side effects and management
Hampig Raphael Kourie et al.
IMMUNOTHERAPY (2016)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects
Giuseppe Bellastella et al.
PITUITARY (2016)
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
Yu Mei et al.
ONCOTARGET (2016)
Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash
Neelima N. Nallapaneni et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
Diabetes Insipidus - Diagnosis and Management
Natascia Di Iorgi et al.
HORMONE RESEARCH IN PAEDIATRICS (2012)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
Troy Dillard et al.
PITUITARY (2010)
Share Paper
